{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:18:20Z","timestamp":1771928300412,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is the second most common hematologic malignancy in adults. Owing to marked heterogeneity in pathogenesis, clinical presentation and prognosis, the 5-year survival rate remains approximately 50%. Robust and clinically actionable biomarkers are therefore urgently needed to refine risk stratification, guide therapeutic decisions and improve prognostic accuracy. ADAM17 (A Disintegrin and Metalloproteinase-17) plays a pivotal role in inflammation, tissue homeostasis and tumorigenesis. Although the research in MM was limited, the existing evidence suggests that ADAM17 may be involved in the pathological process of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, the serum ADAM17 concentrations of 26 MM patients at three different clinical stages (newly diagnosed, remission and progression) were detected by ELISA, and the correlation between ADAM17 concentrations and clinical parameters was analyzed. The expression levels of CD62L on bone marrow T cells of MM patients and healthy donors were compared by flow cytometry. In addition, the above findings were verified in the expanded cohort using the GEO public data set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum ADAM17 concentrations increased progressively from remission to progression and at diagnosis. Levels aligned with DS, ISS and R-ISS staging systems and were strongly associated with renal function. Compared with healthy controls, T cells from MM patients displayed significantly reduced CD62L expression across CD3\n                      <jats:sup>+<\/jats:sup>\n                      , CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      subsets, with the most pronounced loss on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. CIBERSORT analysis revealed significantly higher bone-marrow infiltration of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in patients with low\n                      <jats:italic>versus<\/jats:italic>\n                      high ADAM17 expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data identify ADAM17 as an easily quantifiable, longitudinal biomarker that concurrently reflects tumor development stage and renal function damage in MM patients. Incorporation of ADAM17 into existing risk algorithms may enhance prognostic precision and enable earlier, patient-tailored intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2026.1768193","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:26:10Z","timestamp":1769750770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal profiling of serum ADAM17 across clinical stages in multiple myeloma: a dynamic biomarker and its association with T cell alterations"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiao","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yancheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingshuo","family":"Bao","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jingmen Central Hospital","place":["Jingmen, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiubai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/jco-24-01893","article-title":"International myeloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/emboj\/cdg111","article-title":"TACE is required for the activation of the EGFR by TGF-Alpha in tumors","volume":"22","author":"Borrell-Pag\u00e8s","year":"2003","journal-title":"Embo J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1158\/1078-0432.Ccr-24-0256","article-title":"MYC inhibition potentiates CD8+ T cells against multiple myeloma and overcomes immunomodulatory drug resistance","volume":"30","author":"Davis","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/1078-0432.Ccr-08-1585","article-title":"Role of ADAMs in cancer formation and progression","volume":"15","author":"Duffy","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"152410","DOI":"10.1016\/j.prp.2019.04.002","article-title":"The metalloprotease ADAM17 in inflammation and cancer","volume":"215","author":"D\u00fcsterh\u00f6ft","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.Bcd-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers17091565","article-title":"Prognostic value of post-transplant MRD negativity in standard versus High- and ultra-high-risk multiple myeloma patients","volume":"17","author":"K\u00fcndgen","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-018-0068-5","article-title":"The emerging role of ADAM metalloproteinases in immunity","volume":"18","author":"Lambrecht","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"217775","DOI":"10.1016\/j.canlet.2025.217775","article-title":"ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy","volume":"626","author":"Liu","year":"2025","journal-title":"Cancer Lett."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030321","article-title":"Bone marrow CX3CL1\/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients","volume":"11","author":"Marchica","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/ndt\/gfr583","article-title":"ADAM17 up-regulation in renal transplant dysfunction and non-transplant-related renal fibrosis","volume":"27","author":"Mulder","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.biopha.2011.11.023","article-title":"Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line","volume":"66","author":"Mutlu","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1744980","DOI":"10.1080\/2162402x.2020.1744980","article-title":"ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance","volume":"9","author":"Orme","year":"2020","journal-title":"Oncoimmunology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"F333","DOI":"10.1152\/ajprenal.00625.2018","article-title":"Role of ADAM17 in kidney disease","volume":"317","author":"Palau","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.3390\/cancers13215563","article-title":"ADAM17-A potential blood-based biomarker for detection of early-stage ovarian cancer","volume":"13","author":"Rogmans","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.it.2011.05.005","article-title":"ADAM17: a molecular switch to control inflammation and tissue regeneration","volume":"32","author":"Scheller","year":"2011","journal-title":"Trends Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/jco.2016.67.0893","article-title":"Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia","volume":"35","author":"Sopper","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"15142","DOI":"10.1038\/s41598-024-65937-x","article-title":"Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification","volume":"14","author":"Sun","year":"","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-024-01873-6","article-title":"Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8(+) T cell effector differentiation and anti-tumor immunity","volume":"9","author":"Sun","year":"","journal-title":"Signal Transduct. Target Ther."},{"key":"B22","first-page":"929","article-title":"Serum levels of ADAM10, ADAM12, ADAM17 AND ADAM28 in colorectal cancer patients","volume":"31","author":"Walkiewicz","year":"2017","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"B23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejcb.2011.02.007","article-title":"L-selectin--a dynamic regulator of leukocyte migration","volume":"91","author":"Wedepohl","year":"2012","journal-title":"Eur. J. Cell Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41392-024-01977-z","article-title":"Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNF\u03b1-TRAF3-TAK1-MAPK axis","volume":"9","author":"Xie","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10238-025-01692-1","article-title":"Identification and construction of a novel NET-Related gene signature for predicting prognosis in multiple myeloma","volume":"25","author":"Yan","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12935-023-03007-4","article-title":"Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma","volume":"23","author":"Yu","year":"2023","journal-title":"Cancer Cell Int."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1768193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:26:53Z","timestamp":1771925213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1768193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":26,"alternative-id":["10.3389\/fmolb.2026.1768193"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1768193","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1768193"}}